Markets:

Overview

News

Currencies

International

Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.170 -0.060 (-4.88%)

Streaming Delayed Price Updated: 10:15 AM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm

January 18, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

January 18, 2023

From Law Offices of Howard G. Smith

Via Business Wire

Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?

January 18, 2023

Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.

Via MarketBeat

Topics Stocks

The Law Offices of Frank R. Cruz Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

January 17, 2023

From Law Offices of Frank R. Cruz

Via Business Wire

Over $10 Million Bet On DiamondHead Holdings? Check Out These 4 Stocks Insiders Are Buying ↗

January 17, 2023

Although US stocks closed higher on Friday, there were a few notable insider trades.

Via Benzinga

FATE ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Fate Stockholders and Encourages Investors to Contact the Firm

January 11, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

January 11, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

January 11, 2023

From Law Offices of Howard G. Smith

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

January 11, 2023

From The Law Offices of Frank R. Cruz

Via Business Wire

Top 5 Health Care Stocks That May Surge ↗

January 10, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

How Is The Market Feeling About Fate Therapeutics? ↗

January 09, 2023

Fate Therapeutics's (NASDAQ:FATE) short percent of float has fallen 4.62% since its last report. The company recently reported that it has 20.24 million shares sold short, which is 27.85% of all...

Via Benzinga

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

January 09, 2023

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

January 06, 2023

From The Schall Law Firm

Via Business Wire

CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC ↗

January 06, 2023

Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest.

Via InvestorPlace

Dow Jumps 700 Points; S&P 500 Rises Over 2% ↗

January 06, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday.

Via Benzinga

Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

January 06, 2023

Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

January 06, 2023

Via Benzinga

Nasdaq Gains 1.5%; Fate Therapeutics Shares Plunge ↗

January 06, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 550 points on Friday.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

January 06, 2023

During Friday's trading, 71 companies set new 52-week lows.

Via Benzinga

Greenbrier, Fate Therapeutics, AnaptysBio And Some Other Big Stocks Moving Lower On Friday ↗

January 06, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 500 points on Friday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Is Fate Therapeutics (FATE) Stock Down 62% Today? ↗

January 06, 2023

Fate Therapeutics (FATE) stock is falling on Friday after the company announced the termination of its collaboration with Janssen Biotech.

Via InvestorPlace

Tesla Falls Again, but This Nasdaq Stock Is Truly Plunging ↗

January 06, 2023

The Nasdaq Composite once again is underperforming the rest of the market.

Via The Motley Fool

Fate Therapeutics Ends Collaboration Deal With Janssen, Cuts Staff ↗

January 06, 2023

Via Benzinga

Dow Rises Over 300 Points; US Adds 223,000 Jobs In December ↗

January 06, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 ↗

January 06, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 06, 2023

Via Benzinga

Amarin To Rally 138%? Here Are 10 Other Analyst Forecasts For Friday ↗

January 06, 2023

Via Benzinga

Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket ↗

January 06, 2023

Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

January 06, 2023

The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday!

Via InvestorPlace

Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives

January 05, 2023

From Fate Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.